Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$9.92 USD

9.92
517,509

+0.31 (3.23%)

Updated Apr 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

USANA (USNA) to Report Q2 Earnings: What's in the Cards?

USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.

Theravance Doses First Patient in Phase II Coronavirus Study

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling

Mylan (MYL) beats on Q1 earnings but misses on sales.

Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply

Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.

Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates

Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.

Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.41% and 60.93%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Theravance Pipeline Strong, Dependence on Yupelri a Concern

Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod

AstraZeneca (AZN) gets approval in China for PT010, its triple-combo inhaler, a fixed-dose ICS/LABA/LAMA inhaler, to treat COPD.

Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0.00% and -6.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Pipeline Strong, Dependence on Yupelri a Concern

Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.

AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA

AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.

Theravance Announces Positive Early Data on JAK Inhibitor

Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.

Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises

Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil

Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.